|801-2, Jindong Mansion, No. 536 Xueshi Road, Yinzhou, Ningbo 315100, P.R.Chinafirstname.lastname@example.org|
|Place of Origin:||China|
|Model Number:||10mg, 20mg|
|Minimum Order Quantity:||800 000 tabs|
|Delivery Time:||60 days|
|Supply Ability:||800 000 tabs per day|
|Product:||Atorvastatin Calcium Tablets||Specification:||10mg, 20mg|
|Packing:||10x3/box, 10x10/box||Standard:||BP, USP|
Atorvastatin Calcium Tablets 10mg 20mg 10x3 10x10 Hypolipidemic
Product : Atorvastatin Calcium Tablets
Specification : 10mg, 20mg
Standard : BP, USP
Packing : 10x3/box, 10x10/box
Atorvastatin is a member of the drug class known as statins. It is used for lowering cholesterol. Atorvastatin is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-determining enzyme in cholesterol biosynthesis via the mevalonate pathway. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonate. Atorvastatin acts primarily in the liver. Decreased hepatic cholesterol levels increases hepatic uptake of cholesterol and reduces plasma cholesterol levels.
May be used as primary prevention in individuals with multiple risk factors for coronary heart disease (CHD) and as secondary prevention in individuals with CHD to reduce the risk of myocardial infarction (MI), stroke, angina, and revascularization procedures. May be used to reduce the risk of cardiovascular events in patients with acute coronary syndrome (ACS). May be used in the treatment of primary hypercholesterolemia and mixed dyslipidemia, homozygous familial hypercholesterolemia, primary dysbetalipoproteinemia, and/or hypertriglyeridemia as an adjunct to dietary therapy to decrease serum total and low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (apoB), and triglyceride concentrations, while increasing high-density lipoprotein cholesterol (HDL-C) levels.
Atorvastatin, a selective, competitive HMG-CoA reductase inhibitor, is used to lower serum total and LDL cholesterol, apoB, and triglyceride levels while increasing HDL cholesterol. High LDL-C, low HDL-C and high TG concentrations in the plasma are associated with increased risk of atherosclerosis and cardiovascular disease. The total cholesterol to HDL-C ratio is a strong predictor of coronary artery disease and high ratios are associated with higher risk of disease. Increased levels of HDL-C are associated with lower cardiovascular risk. By decreasing LDL-C and TG and increasing HDL-C, atorvastatin reduces the risk of cardiovascular morbidity and mortality. Atorvastatin has a unique structure, long half-life, and hepatic selectivity, explaining its greater LDL-lowering potency compared to other HMG-CoA reductase inhibitors.
Mechanism of action :
Atorvastatin selectively and competitively inhibits the hepatic enzyme HMG-CoA reductase. As HMG-CoA reductase is responsible for converting HMG-CoA to mevalonate in the cholesterol biosynthesis pathway, this results in a subsequent decrease in hepatic cholesterol levels. Decreased hepatic cholesterol levels stimulates upregulation of hepatic LDL-C receptors which increases hepatic uptake of LDL-C and reduces serum LDL-C concentrations.
Contact Person: Luke Liu
Budesonide Formoterol Inhaler CFC Free 200doses Aerosolized Medications
Pharmaceutical Aerosol Medication , Nitroglycerin Aerosol Spray For Heart Disease
Lidocaine Dental Spray 10% 50ml / 80ml For Intubation , Local Anesthetic Spray
Oral Medications Naproxen Tablets 250mg 500mg for Rheumatoid Arthritis
Synthetic Derivative Ampicillin Capsules 250 mg 500 mg Oral Antibiotic Medications
Antiplatelet Oral Medications Paracetamol Pain Relief Acetaminophen Tablets
Eye / Ear Gentamycin Drops 0.4% 10ml Ophthalmic Preparations Antibiotic Gentamicin Sulfate
Ciprofloxacin Cream Ophthalmic Medication , Ciprofloxacin Eye Ointment
Oxymetazoline Hydrochloride Nasal Spray , 20 ml Nasal Drops 0.025% / 0.05% w/v